NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today a major expansion of its
humanitarian assistance program enabling broader access to its vaccine,
Prevenar 13, in humanitarian emergency settings by offering its new
multi-dose vial (MDV) at what will be the lowest prevailing global
price, currently $3.10 per dose. In addition, given the acute need for
aid on the ground, Pfizer will donate all sales proceeds for the first
year of this program to humanitarian groups undertaking the difficult
work of reaching vulnerable populations in emergency settings. Today’s
announcement of a new and specific pricing tier for civil society
organizations (CSOs) working in emergency settings builds on Pfizer’s
longstanding support for humanitarian emergency relief around the world.
In the immediate term, Pfizer will meet humanitarian emergency needs
through a short-term donation of the single-dose vial of Prevenar 13,
which is available for expedited delivery.
Starting in 2017, refugees can receive the newest version of Prevenar
13, the MDV. This presentation is scheduled to be introduced early next
year and contains four doses of Prevenar 13 in the same-sized vial that
currently contains a single dose. This four-in-one vial is specially
designed to address the unique conditions and challenges experienced in
developing world settings and can help health workers in humanitarian
emergencies. The MDV offers reduced cold storage and transportation
requirements, helping to enable vaccination of children in humanitarian
emergency situations more quickly. It has also been prequalified by the
World Health Organization.
“Pfizer is proud of the significant impact that our Prevenar 13 vaccine
and our partnerships with many humanitarian organizations have had on
public health across the globe. Only by putting the needs of refugees at
the center, can we all work collaboratively to help prevent disease in
some of the world’s most vulnerable populations,” said Susan Silbermann,
President and General Manager, Pfizer Vaccines. “Our new MDV
presentation is an important vaccine technology, and in combination with
our expanded humanitarian assistance program, will provide critical help
in addressing the potential burden of pneumococcal disease in these
populations that might otherwise go unreached. We are especially pleased
to donate all proceeds from these sales to civil society organizations
for the first year to support the significant additional needs these
groups have on the ground.”
Pfizer Humanitarian Assistance Programs
Recognizing the critical need in settings requiring relief and emergency
humanitarian assistance, Pfizer has a three-part approach which includes
product donations, cash grants and other access solutions.
Pfizer donations are focused on specific diseases and designed to
address the needs of people in a coordinated manner. The Company works
with a range of local and global partners, including governments,
health care experts, and CSOs to address the most pressing unmet
medical needs and determine the most effective way for a donation to
meet the needs of affected communities.
Pfizer supports a number of organizations working on providing relief
and emergency humanitarian assistance to address refugee crises. The
Pfizer Foundation provides cash grants to organizations working around
the world to provide health care and other critical support to
Pfizer works closely with governments and CSOs to help provide access
to its vaccines and regularly engages in discussions with partners on
potential new access approaches to reach as many people as possible in
emergency humanitarian situations.
For more information on Pfizer’s Humanitarian Assistance Programs please
About Prevenar 13®
Prevenar 13®*(pneumococcal polysaccharide conjugate vaccine
[13 – valent, adsorbed]) was first approved in the European Union (EU)
in December 2009 for use in infants and young children to help protect
against invasive pneumococcal disease. Prevenar 13® is
approved for such use in more than 150 countries worldwide, including
the United States, Canada, Australia and Japan. Prevenar 13®
is the most widely used pneumococcal conjugate vaccine in the world, and
is included in the pediatric National Immunization Programs in 102
countries.i,ii It is approved in the United States, EU and
other countries for use in infants, older children and adolescents aged
6 to 17 years.
*Trademark. Prevnar 13® is the trade name in the United
States, Canada, and Taiwan.
U.S. IMPORTANT SAFETY INFORMATION
Prevnar 13® should not be given to anyone with a history of
severe allergic reaction to any component of Prevnar 13® or
any diphtheria toxoid–containing vaccine
Children and adults with weakened immune systems (eg, HIV infection,
leukemia) may have a reduced immune response
A temporary pause of breathing following vaccination has been observed
in some infants born prematurely
The most commonly reported serious adverse events in infants and
toddlers were bronchiolitis (an infection of the lungs) (0.9%),
gastroenteritis (inflammation of the stomach and small intestine)
(0.9%), and pneumonia (0.9%)
In children 6 weeks through 17 years, the most common side effects
were tenderness, redness, or swelling at the injection site,
irritability, decreased appetite, decreased or increased sleep, and
Only a healthcare provider can decide if Prevnar 13® is
right for you or your child
For the full prescribing information for Prevnar 13®, please
click here http://www.pfizer.com/products/product-detail/prevnar_13.
Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world's
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world's
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, Pfizer has worked to make a difference for all who
rely on us. For more information, please visit us at www.pfizer.com.
In addition, to learn more, follow us on Twitter at @Pfizer
and like us on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is as of
November 11, 2016. Pfizer assumes no obligation to update
forward-looking statements contained in this release as the result of
new information or future events or developments.
This release contains forward-looking information regarding Prevnar
13/Prevenar 13, including its potential benefits and the expected timing
of the introduction of the four-dose, multi-dose vial (MDV)
presentation, that involves substantial risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements. Risks and uncertainties include, among other
things, risks related to the ability to meet the anticipated timing of
introduction of the MDV presentation of Prevenar 13; uncertainties
regarding the commercial impact of the MDV presentation of Prevenar 13;
uncertainty regarding whether the anticipated benefits of the World
Health Organization prequalification will be realized; decisions by
regulatory authorities regarding labeling and other matters that could
affect the availability or commercial potential of Prevnar 13/Prevenar
13; and competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2015 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results”, as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
i Data on file. Pfizer Inc, New York, NY. [Total Prevenar 13V
Doses Through May 2016]
ii GlaxoSmithKline. GSK’s Synflorix™ receives CHMP positive
opinion for major label extension. July 27, 2015. http://www.gsk.com/en-gb/media/press-releases/2015/gsk-s-synflorix-receives-chmp-positive-opinion-for-major-label-extension/.
Accessed July 7, 2016.